Eliminating PD‐L1 on Dendritic Cell Extracellular Vesicles for Immunotherapy Potentiates Immune‐Mediated Tumour Rejection in Mice
Journal of Extracellular Vesicles · 2026-07 · 15 (7)
DOI: 10.1002/jev2.70322 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Extracellular Vesicles, online erschienen am 30.06.2026. Verfasst von Loes Teeuwen und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Immunology and Respiratory Medicine, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden. Hauptthemen laut MEDLINE: Extracellular Vesicles, Dendritic Cells, B7-H1 Antigen, Immunotherapy. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Swedish Medical Research Council, The Swedish Cancer Society, The Cancer Research Foundations of Radiumhemmet.
Abstract (Originalsprache)
Extracellular vesicles (EVs) are emerging as promising vehicles for cancer immunotherapy, yet the molecular determinants of their immunogenicity remain poorly defined. While PD‐L1 expression on cancer‐derived EVs has been shown to suppress immune responses, its role on immunotherapeutic EVs remains unexplored. In this study, we investigated how eliminating PD‐L1 from antigen‐loaded bone marrow‐derived dendritic cell (BMDC) EVs affects the efficacy of EV‐based cancer vaccines. We generated and characterized ovalbumin (OVA)‐loaded BMDC EVs from wild‐type (WT) and PD‐L1 −/− C57BL/6 mice. EVs were administered intravenously into WT mice in immunization experiments and in therapeutic and prophylactic B16 OVA‐secreting melanoma models. Immune responses were assessed by flow cytometry, ELISpot, and ELISA, and tumour growth was monitored. Proteomic analysis confirmed high EV purity and similar protein profiles between WT and PD‐L1 −/− EVs, with PD‐L1 being the major difference. Functionally, PD‐L1 −/− EVs induced significantly stronger anti‐tumour responses in vivo, particularly in the prophylactic setting. Mice treated with PD‐L1 −/− EVs showed increased CD8 + T cell tumour infiltration, enhanced IFNγ secretion, and higher tumour rejection rates compared to WT EVs (72.7% vs. 37.5%). Additionally, the frequency of tumour‐infiltrating, antigen‐specific CD8 + T cells was significantly higher in PD‐L1 −/− EV‐treated mice. In summary, BMDC‐derived EVs loaded with antigen are potent immune stimulators, and removal of immune checkpoint molecules such as PD‐L1 further enhances their immunogenicity. These findings support the development of engineered EVs as improved platforms for cancer immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Immunology and Respiratory Medicine, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.
- Department of Clinical Immunology and Transfusion Medicine, Karolinska University Hospital, Stockholm, Sweden.
- Center for Molecular Medicine (CMM), Karolinska University Hospital, Stockholm, Sweden.
- Department of Medicine Huddinge, Center for Infectious Medicine, Karolinska Institutet, Stockholm, Sweden.
- Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden.
ORCID-Profile: Loïc Steiner, Chantal Reinhardt, Susanne Gabrielsson
Förderung
- The Swedish Medical Research Council
- The Swedish Cancer Society
- The Cancer Research Foundations of Radiumhemmet
- Karolinska Institutet's KID grant
- Karolinska Institutet Foundations
Zitieren
APA
Teeuwen, L., Steiner, L., Reinhardt, C., Offens, A., Kuipers, J. E., Martínez-Martínez, D., Mazouin, J., Chambers, B. J., Güçlüler Akpinar, G., & Gabrielsson, S. (2026). Eliminating PD‐L1 on Dendritic Cell Extracellular Vesicles for Immunotherapy Potentiates Immune‐Mediated Tumour Rejection in Mice. Journal of Extracellular Vesicles, 15(7). https://doi.org/10.1002/jev2.70322
Vancouver
Teeuwen L, Steiner L, Reinhardt C, Offens A, Kuipers JE, Martínez-Martínez D, et al. Eliminating PD‐L1 on Dendritic Cell Extracellular Vesicles for Immunotherapy Potentiates Immune‐Mediated Tumour Rejection in Mice. Journal of Extracellular Vesicles. 2026;15(7). doi:10.1002/jev2.70322
BibTeX
@article{Teeuwen2026,
author = {Teeuwen, Loes and Steiner, Loïc and Reinhardt, Chantal and Offens, Annemarijn and Kuipers, Jesse E and Martínez-Martínez, Daniel and Mazouin, Jules and Chambers, Benedict J and Güçlüler Akpinar, Gözde and Gabrielsson, Susanne},
title = {Eliminating PD‐L1 on Dendritic Cell Extracellular Vesicles for Immunotherapy Potentiates Immune‐Mediated Tumour Rejection in Mice},
journal = {Journal of Extracellular Vesicles},
year = {2026},
volume = {15},
number = {7},
doi = {10.1002/jev2.70322}
}
EUVIMED